arrow
M

Maria Paola Martelli

University of Perugia
H指数:87
被引数:3.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Optimising CPX-351 (liposomal cytarabine-daunorubicin) treatment for t-AML/AML-MRC patients in the outpatient setting: a modified Delphi consensus

优化门诊环境下CPX-351(脂质体阿糖胞苷-柔红霉素)治疗t-AML/AML-MRC患者的方案:一项改良德尔菲共识

2026-09-110
OA
Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial

非适应证急性髓系白血病患者接受维奈克拉联合去甲基化药物的疗效:GIMEMA AML2320试验结果

2026-09-050
PRE
Use of Peripheral Blood to Measure Residual Disease by Flow Cytometry in Adult Acute Myeloid Leukemia: Final Report of the Prospective GIMEMA AML1310 Trial

使用外周血通过流式细胞术测量成人急性髓系白血病残留病灶:GIMEMA AML1310前瞻性试验的最终报告

2026-09-020
OAAI
Dynamics of in vivo immune remodeling in Ph+ all patients receiving frontline ponatinib and blinatumomab therapy

Ph+ ALL患者接受一线ponatinib和blinatumomab治疗后的体内免疫重塑动力学

2026-08-120
OA
Rab GTPases drive ligand-independent NOTCH1 activation via altered endocytic trafficking in chronic lymphocytic leukemia

Rab GTP酶通过改变内吞转运驱动慢性淋巴细胞白血病中配体非依赖的NOTCH1激活

2026-07-290
OAAI
Durable remission despite transplantation with active disease in therapy-related NUP98::TOP1-rearranged acute myeloid leukemia

尽管伴有活动性疾病的移植治疗,NUP98::TOP1重排的急性髓系白血病仍能获得持久缓解

2026-05-230
OAAI
A specific stem cell program and CD112 immunological axis dysfunctions underpinning monosomy 7-associated myeloid neoplasms

特定的干细胞程序和CD112免疫轴功能障碍是7号单体相关髓系肿瘤的基础

2026-05-110
OAAI
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort
2026-01-130
OAAI
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry program

blastic plasmacytoid dendritic cell neoplasm (BPDCN):国际、多中心合作和全球登记项目

2025-12-210
OAAI
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

根据SIE/SIES/GITMO标准对治疗相关和aml-mrc接受CPX-351的适应性分类的影响。

2025-12-110
OAAI
Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia

更正:CPX-351在60岁以下继发急性髓系白血病患者中的真实世界多中心疗效分析

2025-12-040
OAAI
Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients

Gilteritinib在二线治疗后的有效性:一项关于171例复发/难治性FLT3突变急性髓系白血病患者的真实世界多中心研究

2025-11-010
OAAI
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia

真实世界多中心分析CPX-351在60岁以下继发性急性髓系白血病患者中的疗效

2025-10-260
OA
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation

真实世界研究:异基因干细胞移植的最佳CPX-351治疗时长与时机

2025-09-240
OAAI
Venetoclax plus azacitidine as genetic-driven bridge-to-transplant therapy for IDH2-mutated acute myeloid leukaemia (AML) refractory to intensive chemotherapy: proof-of-concept case reports

维奈克拉联合阿扎胞苷作为IDH2突变型急性髓系白血病(AML)对强化化疗耐药时的基因驱动桥接移植疗法:概念验证病例报告

2025-07-080
OAAI
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents

接受维奈克拉联合表观遗传药物治疗的患者的生存情况受治疗前合并症负担的影响

2025-01-200
OAAI
Treg Selection from G-CSF Stimulated Donors Improves Outcomes of Immune-Suppression Free HLA-Haploidentical Hematopoietic Cell Transplantation with T Cell Adoptive Immunotherapy

Treg从G-CSF刺激的供者中筛选可改善无免疫抑制的HLA单倍体匹配造血细胞移植联合T细胞过继免疫治疗的疗效

BLOOD
IF23.1
2024-11-050
PRE